Company: MDCXW
Filing Date: 2025-12-10
Form Type: DRS
Source: 0001062993-25-017281
Chunk: 24

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-10
Form: DRS
Chunk 24
---
SEC") nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>Maxim Group LLC

The date of this prospectus supplement is , 2025.

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83

TABLE OF CONTENTS

Prospectus</div>

| ABOUT THIS PROSPECTUS SUPPLEMENT                      | S-1  |
| TRADEMARKS, TRADE NAMES AND SERVICE MARKS             | S-3  |
| MARKET, INDUSTRY AND OTHER DATA                       | S-4  |
| CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS | S-5  |
| PROSPECTUS SUMMARY                                    | S-7  |
| THE OFFERING                                          | S-11 |
| RISK FACTORS                                          | S-12 |
| USE OF PROCEEDS                                       | S-15 |
| DESCRIPTION OF COMMON SHARES                          | S-16 |
| DILUTION                                              | S-17 |
| PLAN OF DISTRIBUTION                                  | S-19 |
| LEGAL MATTERS                                         | S-21 |
| EXPERTS                                               | S-21 |
| WHERE YOU CAN FIND MORE INFORMATION                   | S-21 |
| INFORMATION INCORPORATED BY REFERENCE                 | S-21 |
| PART II  INFORMATION NOT REQUIRED IN PROSPECTUS       | II-1 |
| SIGNATURES                                            | II-9 |

<div align='center'>S-i

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83

ABOUT THIS PROSPECTUS SUPPLEMENT</div>

This prospectus supplement relates to part of a registration statement on Form S-3 that we have filed with the SEC utilizing a "shelf" registration process. Under this shelf registration process, we may sell any combination of the securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $100,000,000. The $16,714,107 common shares that may be offered, issued and sold under this prospectus supplement is included in the $100,000,000 of securities that may be offered, issued and sold by us pursuant to our shelf registration statement.